Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084176 | 0.99 | HRH3 (0.50) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084152 | 0.98 | HRH4 (0.47) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084156 | 0.97 | HRH3 (0.48) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084145 | 0.94 | HRH4 (0.49) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084177 | 0.93 | HRH4 (0.48) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084110 | 0.78 | HRH4 (0.51) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084153 | 0.77 | HRH4 (0.52) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084160 | 0.76 | HRH4 (0.51) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL4736079 | 0.76 | HRH3 (0.52) | HRH3ADORA1ADORA2AHRH4HRH2 | |
| SCHEMBL14084147 | 0.75 | HRH4 (0.52) | HRH3ADORA1ADORA2AHRH4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH3 3492/4885ADORA1 2541/4885ADORA2A 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.